Drug Database
HE

hepatitis-A/typhoid vaccine (Hepatyrix)

✓ Approved

GSK · 疫苗 · 疫苗

什么是 hepatitis-A/typhoid vaccine?

hepatitis-A/typhoid vaccine 是一种疫苗,由GSK研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intramuscular (IM) Injection。

药物档案

商品名Hepatyrix
公司GSK
药物类别疫苗
给药途径Injectable (Others), Intramuscular (IM) Injection
状态Approved

治疗适应症

hepatitis-A/typhoid vaccine 针对 2 个适应症,涉及 2 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsTyphoid fever✓ Approved
Surgical and medical proceduresAntiviral prophylaxis✓ Approved

相关研究文献

PubMedRSC advances2026-09-10

Synthesis of Sb(iii)-immobilized on nitrogen-doped mesoporous silica nanotubes for efficient and green preparation of pyrazolopyranopyrimidines: comprehensive characterization, green chemistry evaluation and computational antifungal profiling against 5TZ1.

Jafari Taadi Zahra Z, Moradi Leila L, Moazeni Bistgani Azam A

In this study, a novel heterogeneous nanocatalyst, Sb(iii) immobilized on nitrogen-doped mesoporous silica nanotubes (N-MSNTs/Sb(iii)), was successfully synthesized. This catalyst was then applied in a one-pot, four-component synthesis of pyrazolopyranopyrimidine derivatives via the condensation of ethyl acetoacetate, hydrazine hydrate, aromatic aldehydes, and barbituric/thiobarbituric acid. Comprehensive characterization using FT-IR, FE-SEM, EDS, HR-TEM, XRD, and BET/BJH analyses confirmed its structural features. Notably, HR-TEM revealed hollow nanotubular structures with an inner diameter of ∼23 nm and a wall thickness of 27 nm. Moreover, BET/BJH measurements exhibited a type IV isotherm, indicative of a highly porous structure, with a remarkable specific surface area of 1255 m2 g-1, a pore volume of 0.71 cm3 g-1, and an average pore diameter of 2.26 nm. Catalytic evaluations demonstrated the superior performance of N-MSNTs/Sb(iii) in aqueous media at room temperature, affording the target compounds in high yields (78-96%) within short reaction times (35-85 min). This remarkable efficiency stems from synergistic activation of support by the nitrogen sites and active Sb(iii) Lewis acidic species. Furthermore, the catalyst exhibited excellent stability, maintaining its initial activity over five consecutive reuse cycles. Finally, molecular docking simulations were performed against the antifungal target 5TZ1. The results confirmed that the carbonyl and NH groups within the synthesized molecular scaffolds establish favorable binding interactions, highlighting the promising drug-like properties of the final products.

PMID 42719317
阅读全文 →
PubMedJournal of virology2026-09-10

Virus-specific T cells and neutralizing antibodies are independent correlates of long-term protective immunity against hepatitis C virus.

Gomez-Escobar Elsa E, Siddique Asiyah A, Khedr Omar O, Bédard Nathalie N et al.

Virus-specific T cells and broadly neutralizing antibodies (NAbs) are associated with spontaneous clearance of acute primary hepatitis C virus (HCV) infection and reinfection. Following spontaneous clearance, HCV-specific memory T cells are long-lived, but NAbs are less durable. How these two arms contribute to long-term protective immunity upon re-exposure is unknown. Herein, we compared the magnitude and breadth of memory HCV-specific T cells and NAbs in a cohort of HCV-spontaneously resolved people who inject drugs with high-risk exposure to the virus but who remained free of observed reinfections (FOR, n = 34) or who got reinfected (n = 22). Among FOR, 73.5% (n = 25) exhibited high frequencies of gamma interferon (IFN-γ)-producing T cells, while 23.5% (n = 8) showed high neutralization breadth (>25% neutralization of HCV pseudoparticles [HCVpp]) and/or potency (geometric mean neutralization >50% against seven HCVpp). Notably, some subjects had detectable NAbs several years after clearance. Multivariate random forest analysis demonstrated that the frequency of IFN-γ-producing T cells and the NAb response against only one difficult-to-neutralize HCVpp (1b58) were significant predictors of protection against reinfection (P < 0.05). Longitudinal analysis of the immune response in subjects with multiple episodes of infection showed that strong and broad HCV-specific T cell responses were associated with spontaneously cleared episodes. In contrast, NAbs did not protect from chronicity upon re-exposure in the absence of memory T cells, or if they were unable to recognize the infecting virus due to imprinting by strains of the previous episodes. In conclusion, T cell responses and NAbs targeting specific isolates are independent predictors of long-term protective immunity against HCV. Hepatitis C virus (HCV) is a blood-borne virus that disproportionately affects people who inject drugs. Most HCV infections become persistent, leading to liver fibrosis and cancer. Although effective antiviral therapies are available, around 50 million people remain persistently infected with HCV and can transmit the virus. Currently, there is no available vaccine to control the spread of HCV. However, around one in four people infected can naturally clear the virus, becoming partially protected upon re-exposure, suggesting it is possible to develop a vaccine that induces similar protection. In this study, we investigated the contribution of T cells and neutralizing antibodies to protection against observed reinfection in a cohort of people who inject drugs and have naturally cleared HCV, yet remain at high-risk exposure. Our findings suggest that strong T cell responses and neutralizing antibodies targeting hard-to-neutralize isolates could predict protective immunity upon reinfection.

PMID 42720294
阅读全文 →
PubMedFrontiers in immunology2026-09-10

A bivalent oral yeast vaccine displaying Nocardia seriolae FHA and LMBV MCP confers protection in largemouth bass (Micropterus salmoides).

Lu Jianfei J, Gu Boge B, Yu Pengzhen P, Chen Jiong J

Largemouth bass ranavirus (LMBV) and Nocardia seriolae are major pathogens affecting largemouth bass (Micropterus salmoides), causing significant economic losses. In this study, recombinant yeasts expressing the fibronectin-binding protein A (FHA) of N. seriolae or the major capsid protein (MCP) of LMBV were constructed using the yeast surface display (YSD) system. Based on these recombinant strains, a bivalent oral yeast-based vaccine was developed and its protective efficacy was systematically evaluated. Oral administration of the vaccine induced specific antibodies against FHA and MCP in serum, as well as increased the transcription levels of adaptive immune genes (IgM, IgT, MHC-II) and innate immune genes (IL-1β, TNF-α, IFN-1, Mx2) in the hindgut, liver, and spleen. Importantly, the bivalent oral vaccine provided significant protection against both pathogens in largemouth bass, with relative percent survival (RPS) values of 56.7% against N. seriolae and 63.3% against LMBV. Meanwhile, the oral vaccine reduced pathogen loads and alleviated histopathological lesions. In summary, these findings suggest that the bivalent oral vaccine developed in this study could serve as a promising strategy for controlling N. seriolae and LMBV infections in largemouth bass aquaculture.

PMID 42718698
阅读全文 →
PubMedEpidemiologia e servicos de saude : revista do Sistema Unico de Saude do Brasil2026-09-10

Hepatitis A among people experiencing homelessness: a case series, Curitiba, Paraná State, Brazil, 2023-2024.

Silva Janilza Silveira JS, de Carvalho Renata Barbosa Vilaça Marques RBVM, de Oliveira Alcides Souto AS, Dos Santos Diego Spinoza DS et al.

To describe hepatitis A cases among people experiencing homelessness in Curitiba, Paraná State, Brazil, in 2023-2024. This case series included people experiencing homelessness who were reported with hepatitis A in the Notifiable Diseases Information System between November 1, 2023, and May 29, 2024, in Curitiba. This population was identified by reviewing electronic medical records and the registry database of the Consultório na Rua [Street Outreach Clinic] team. Sociodemographic, clinical, and laboratory variables were extracted. Of 281 reported cases, 18 (6.4%) occurred among individuals experiencing homelessness; 16 were male. The mean age was 31±7 years. Regarding substance use in this population, 17 individuals reported crack cocaine use and 14 reported alcohol use. Mean aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels were 1,290.94 (±1,144.82) U/L and 1,558.13 (±1,050.00) U/L, respectively. The mean total bilirubin level at clinical presentation was 5.29 (±3.59) mg/dL, and jaundice was present in 55.6% of cases. Two deaths were recorded among the 18 cases in individuals experiencing homelessness (mortality: 11.1%), compared with three deaths among the remaining 263 reported cases (mortality: 1.1%). Symptoms of acute liver failure were observed in hepatitis A cases among people experiencing homelessness, all of whom required hospitalization; deaths were also reported.

PMID 42718314
阅读全文 →
PubMedTherapeutic advances in infectious disease2026-09-10

Association of alanine aminotransferase flares with hepatitis B surface antigen loss and clinical outcomes in treated and untreated patients with chronic hepatitis B virus infection: A US retrospective cohort study.

Drysdale Myriam M, Morais Eleonora E, Chang Rose R, Wang Shuang S et al.

Previous research has demonstrated the clinical significance of alanine aminotransferase (ALT) flares; however, studies have mostly been in Asian countries or populations, and it remains unclear whether ALT flares during treatment are associated with hepatitis B surface antigen (HBsAg) loss and long-term adverse clinical outcomes. To evaluate the association between ALT flares and virologic outcomes (HBsAg and hepatitis B e antigen [HBeAg] loss) as well as adverse clinical outcomes among patients with chronic hepatitis B in the United States, according to treatment status. Retrospective study using the Optum de-identified electronic health record dataset (2012-2019). Marginal structural models estimated the associations between ALT flares and outcomes, accounting for time-varying confounding; adjusted odds ratios and 95% confidence intervals were reported. A Cox proportional hazards regression model was used to assess risk factors for flares. 14,328 patients were included in the untreated cohort; of these, 2298 (16.0%) initiated and 1541 (10.7%) subsequently discontinued treatment. At least one ALT flare was experienced by 364 patients (2.5%) in the untreated cohort, 84 (3.7%) in the treatment initiation cohort, and 22 (1.4%) in the discontinuation cohort. Risk factors for ALT flares in the untreated group included male sex, history of flares, metabolic syndrome, liver fibrosis, compensated cirrhosis (CC), and hepatic decompensation. Risk factors after treatment initiation included younger age, White race, history of flares, and evidence of liver damage (liver fibrosis, CC, or hepatic decompensation). Flares in the untreated group were associated with spontaneous HBsAg loss and with an increased risk of hepatic decompensation, hospitalization, and death. Flares after treatment initiation were associated with HBsAg and HBeAg loss but not with adverse clinical outcomes investigated. ALT flares in untreated patients were associated with virologic and adverse clinical outcomes; no association with adverse clinical outcomes was observed in patients who initiated treatment.

PMID 42719439
阅读全文 →
PubMedMicrobiology resource announcements2026-09-10

Genomic characterization of the attenuated human cytomegalovirus strain TR-VAC developed for subviral particle vaccine production.

Schmidt Hanno H, Hewel Charlotte C, Büscher Nicole N, Linke Matthias M et al.

We report the complete genome sequence of the attenuated human cytomegalovirus strain TR-VAC, developed for subviral particle vaccine production. Oxford Nanopore duplex sequencing confirmed all engineered modifications, including UL130 repair, UL25 stop codons, ddFKBP insertion, GFP deletion, and retention of the bacterial artificial chromosome backbone, without large-scale structural rearrangements.

PMID 42720293
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多hepatitis-A/typhoid vaccine